Where digital access to life-saving solutions is made possible.
BIOSPHERES is a new channel
A channel that is possible
because of the blockchain revolution.
A channel that gives the patients a say
in what is important to their own health and for their future generations.
A channel that allows medical innovations to be born
into the world without being limited to an institution that prioritizes profit over people.
A channel that invites and connects
researchers, patients and the medical community to collectively support initiatives that will benefit our lives while simultaneously creating a financial and health benefit for everyone involved.
The Biospheres Ecosystem
Everyone needs medical care—whether it’s preventive, palliative, or curative. High-quality medical care is made possible through patient empowerment—by hearing out the needs and concerns of the public.
The current health industry model relegates patients to the passive-payer role. While many projects are trying to change this, very few are able to empower patients by using their direct feedback and purchasing power.
Biospheres leverages these unsaid needs and built-up demand by allowing patient purchases to dictate which research trends, projects, and products make it ahead of the game. Patients become curators and customers. With this power to decide which treatment reservations gain attention and real-world demand, we are creating a new opportunity for demand metrics and price discovery.
Alongside this democratized ecosystem comes flexibility, transferability, cost reduction, and consumer protection through refund programs.
The world is filled with brilliant innovators—scientists, biotech companies, and independent biopharma firms—at various stages of research, development, and commercialization.
Biospheres provides an opportunity for these innovators to list their projects, products, and services in the form of reservation tickets prior to their release/distribution.
This creates a vibrant marketplace for these initiatives to thrive and to get financed through alternative means, all the while not having to give up equity and ensure that their projects are sustained in the long run.
Biospheres’ non-dilutive financing model is all about helping innovators get the resources they need to bring their brilliant discoveries faster to help the people.
Redefining the Future of Medical Breakthroughs
Aevolve redefines how innovations are developed and released to the market. Through Biospheres, openness, and transparency about the process is created. The platform also supports projects at different stages of their development.
Supporting the Stages of the Innovation Life-Cycle.
Early Stage Research & Discovery
DRIVEN BY GENIUS
Community Driven Challenge Funds
DRIVEN BY NEED
Research and Product Development
DRIVEN BY DETERMINATION
At this point, research blends with business more than ever. The product has already been conceptualized, patent filings are established or are underway and a company is formalized to house the research work, technology IP and investments necessary to fuel the development work. These companies are already working with relevant regulatory bodies such as the FDA to develop research and commercialization analysis.
Those that are successful with capital access in this very expensive stage can find hope to move to the next level. But this is a risky space. It is to the point where most biotechnology and medical innovation funds will receive and filter through hundreds and even thousands of projects per year only to pick 5 to 10 in hopes one will perform. That means the company must have extremely competitive circumstances that must be properly recognized to even be a candidate for these traditional capital pools. And as investment resources naturally centralize, the existing and new projects will begin to compete for the same sources. But, besides the innovation, what else can be done?
BIOSPHERES provides a platform where these companies can create visibility by both the global patient community and to the angel and institutional investor communities. Beyond acceptance, our Grant and Challenge Fund engines can accelerate companies in terms of progress and eventually, value. But more importantly, engagement by the community shows that the market access and opportunity is in reach and that is where the investors can see beyond just the technology that business opportunity is at hand. For investors, this creates a channel for opportunities with an added dimension of value and creative experimentation for value creation.
Commercial Ready, Distribution, Growth
DRIVEN BY THE PEOPLE
Products that offer a medical solution to a consumer but do not require FDA approval such as a food-based product or diagnostic service.
Products that are already existing and selling in the market (all regulatory requirements are fulfilled) and the company seeks to expand its offering either geographically or increase its inventory and distribution capabilities.
Products that are given limited FDA approvals like Orphan Drugs where they are allowed to commercialize on a limited basis and are still undergoing clinical research activity.
- Products that are given full commercialization FDA approval for human use which can include both prescription and non-prescription based medical services.
THE NEW PATH TO PATIENT-DRIVEN TREATMENTS AND CURES
Aevolve is a protocol that supports medical innovations from R&D stages to full-scale commercialization, by connecting patients, investors, and scientific innovators.
FOR PATIENTS AND INNOVATORS
This innovation marketplace connects patients and the global community directly with scientific innovators and experts from all over the world to address various stages of the innovation life cycle.
INVESTOR ACCESS TO A BILLION-DOLLAR ECOSYSTEM
This new asset class provides exposure to opportunities in blockchain, free of the risks associated with previous token offerings. Coming soon to the the SIX Swiss Stock Exchange.
AVEX! Token & The Aevolve Protocol
Cutting-edge medical science meets blockchain-driven technology to create new opportunities to drive innovation.